Browse studies

Find your next paid study

1 recruiting study matching your filters

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identi…

High Risk CancerPancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05013216